The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell
Authors:
- Juan LinJLJuan Lin
- Yuping GongYGYuping Gong
- Tianyou YanTYTianyou Yan
- Fangfang ShiFSFangfang Shi
- Xi YangXYXi Yang
- Xuehua LiuXLXuehua Liu
- Duolan NarenDNDuolan Naren
- 1 October 2015
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 26 (9) , 913-922
Abstract
In recent years, there have been considerable research advances on the antileukemic mechanisms of the antidiabetic drug metformin. Our current studies have shown that metformin suppresses cell viability, induces apoptosis, and downregulates the mTORC1 signaling pathway both in the Ph+ALL cell line and primary blasts from Ph+ ALL patients, as well as the CML cell lines K562 (imatinib-sensitive) and K562R (imatinib-resistance). We have also shown that metformin activates the ERK pathway in Ph+ALL cells, SUP-B15, a side effect that can be overcome by U0126 (MEK1/2 inhibitor) or imatinib. Moreover, this activation of ERK signaling in SUP-B15 induces autophagy. Inhibition of the autophagic process by 3-MA, promoting the death of these cells, suggests that autophagy may be a cytoprotective factor in cell survival after metformin treatment. Finally, metformin is shown to potentiate the anticancer efficacy of imatinib in Ph+ALL and CML cells, resensitizing the CML imatinib-resistance cells to imatinib. Overall, our data suggest that metformin represents a promising and attractive agent for Ph+ALL or CML therapy.Keywords
This publication has 29 references indexed in Scilit:
- New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent2013
- Metformin and cancerEuropean Journal of Pharmacology, 2013
- Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment OptionsCurrent Oncology Reports, 2012
- AMPKα Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric CancerCancer Research, 2012
- Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysisPLOS ONE, 2012
- Metformin in cancer: translational challengesJournal of Molecular Endocrinology, 2012
- Metformin and neoplasia: Implications and indicationsPharmacology & Therapeutics, 2012
- Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 2010
- Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 2009
- Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialBlood, 2006